Quick Facts

• Therapeutic Domain: Pain related to osteoarthritis (OA) of the knee.
• Patient Group: Individuals who have not responded adequately to non-pharmacological therapy (e.g., exercise) and simple pain relievers.
• Primary Benefit: May help relieve pain and support joint function.

---

MONOVISC is used to address pain associated with osteoarthritis (OA) of the knee joint. This prescription device is typically reserved for individuals whose symptoms have not sufficiently responded to more conservative management approaches, such as physical therapy, activity modification, or simple over-the-counter pain medication like acetaminophen.

As a treatment administered directly into the knee, MONOVISC may function as a supplement to the synovial fluid, which is naturally present in the joint space. The goal of this intra-articular application is to help with joint cushioning and lubrication, which may contribute to a reduction in pain symptoms and support improved joint function. MONOVISC is designed to provide pain relief for a proportion of patients who have not achieved adequate results with first-line treatments. This treatment offers a therapeutic option intended to help manage the chronic discomfort of knee OA.

MONOVISC (high molecular weight hyaluronan) is approved for use in patients with osteoarthritis (OA) of the knee whose pain has not been adequately relieved by conservative non-drug therapies and simple pain relievers, such as acetaminophen.

Contraindications and Restrictions

MONOVISC should not be administered to certain populations due to specific risks or lack of established data. Use is contraindicated in patients with:

• Known hypersensitivity (allergy) to hyaluronate preparations.
• Known hypersensitivity (allergy) to gram positive bacterial proteins.
• Infections or skin diseases in the area of the injection site or joint.
• Known systemic bleeding disorders.

Use is not established and has not been tested for:

• Pregnant women.
• Nursing (lactating) mothers.
• Pediatric patients (le 21 years of age). The safety and effectiveness in these age groups and physiological states have not been determined by regulatory bodies.

The official regulatory documentation for MONOVISC (Sodium Hyaluronate) defines its interaction profile primarily through site-specific administration constraints rather than systemic pharmacokinetic effects.

Interacting Substances and Required Restrictions

Category	Officially Documented Constraint
Chemical Incompatibility	Co-administration of disinfectants containing quaternary ammonium salts for skin preparation is strictly prohibited.
Interaction Outcome	Contact between quaternary ammonium salts and the hyaluronan component results in the precipitation of the product due to chemical incompatibility.
Concomitant Use Restriction	The safety and effectiveness of administering MONOVISC concomitantly with other intra-articular injectables has not been established.

Pharmacokinetic and Systemic Interactions

Consistent with its localized method of administration as a viscosupplement, the official regulatory prescribing information does not document any systemic metabolic interactions. There are no listed interactions involving cytochrome P450 (CYP) enzymes, drug transporters, or any resulting alteration in plasma exposure (AUC/Cmax) of co-administered medicines. Furthermore, the regulatory labeling does not contain any documented interactions with food, alcohol, herbal products, or dietary supplements. The entire interaction profile is centered on local chemical compatibility and restrictions on combination use within the joint space.

️ Biophysical Restoration of Joint Viscoelasticity

MONOVISC's primary action is viscosupplementation, which involves the physical delivery of high molecular weight Sodium Hyaluronate (HA) directly into the Synovial Fluid. The interaction is biophysical: the substance supplements the deficient native fluid, restoring the essential viscosity and elasticity (rheology). This alteration in fluid mechanics is the initial phase of the mechanism, establishing the required rheological properties, which contributes to the fluid's ability to resist deformation under mechanical stress.

️ Mechanical Offloading and Nociceptor Dampening

The restored viscoelastic properties facilitate optimal boundary lubrication and shock absorption, significantly reducing the mechanical stress and friction exerted on the Articular Cartilage surfaces during motion. This mechanical offloading is critical: by creating a physical buffer, the treatment physically prevents abrasive forces from over-stimulating structures. This physical barrier reduces stimulation of nociceptive nerve endings within the joint structures, directly influencing the mechanical component of afferent signaling.

Cellular Modulation and Matrix Influence

Beyond the mechanical effects, the HA molecule also engages in secondary physiological modulation. It interacts with cells like synoviocytes, potentially encouraging the joint's intrinsic ability to synthesize its own native HA. Furthermore, the presence of high molecular weight HA modifies the conditions within the intra-articular environment. The HA molecule is documented to influence the activity of cartilage-degrading enzymes, such as Matrix Metalloproteinases (MMPs). This localized modulatory effect supports cellular functions relevant to the structural integrity of the joint matrix.

The administration of MONOVISC is defined as a single, specialized procedure for the knee joint.

---

Administration Route and Dose

The product is indicated exclusively for intra-articular injection into the knee joint. It is administered as a single dose of 4.0 mL per treated knee, which delivers 88 mg of Sodium Hyaluronate. The effectiveness of MONOVISC has not been established for more than one course of treatment, resulting in a single administration per course.

---

Procedural Requirements

The injection must be carried out by a qualified, licensed practitioner trained in accepted injection techniques, emphasizing the mandatory professional setting. The procedure includes the removal of any synovial fluid or effusion from the joint prior to the injection, and the use of a separate syringe for this task. Strict aseptic technique must be maintained, and disinfectants containing quaternary ammonium salts should not be used for skin preparation, as these agents can cause precipitation. If both knees are treated, a separate, single-use syringe must be designated for each joint.

---

Administration Constraints

Following the procedure, patients are advised to avoid strenuous or prolonged weight-bearing activities such as jogging, tennis, or heavy lifting for a period of 48 hours. Use of this product is limited to the adult population, as the safety and effectiveness have not been established in pediatric patients.

Research Evidence / Overview of Studies for MONOVISC

Evidence for use in Osteoarthritis of the Knee

Research involving MONOVISC was conducted in individuals with symptoms of osteoarthritis of the knee, a condition marked by functional limitations and outcomes related to physical discomfort. Research primarily examined the injection in short-term randomized, controlled trials (RCTs). These studies included adults diagnosed with mild to moderate knee osteoarthritis. The RCTs monitored patient experiences by measuring patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level, typically over a period of up to 26 weeks.

Findings describe patterns observed in the studies over the short follow-up periods. Some trials reported measurements of knee pain, indicating that participants receiving MONOVISC described patterns in their reports of discomfort during the study period. Other research explored changes in how participants reported their ability to carry out everyday activities, such as walking or climbing stairs. The evidence describes symptom patterns over the short term. It is important to note that the results apply only to the populations studied and that findings were mixed across various research trials.

Long-term Studies and Follow-up

Research was evaluated in settings where the follow-up durations were limited, typically to six months or less. This means that long-term effects are not fully established regarding the use of MONOVISC. Extended studies research explored whether any observed changes in outcomes related to physical discomfort or function was observed in patients beyond the typical six-month mark. The available data are still emerging regarding extended follow-up of these observations over time intervals. There is limited information for long-term outcomes regarding how the injection was associated with the overall progression of the condition involving periods of heightened symptoms over many years.

What is Still Uncertain about MONOVISC

A significant limitation is that the sample sizes were modest in some of the main research studies, which can limit the overall certainty of the observations. Furthermore, evidence quality varies across studies, and some observations were collected from open-label or non-randomized settings. This means that certainty about these findings may be limited in some aspects of the research. The research provides context but not individual predictions. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in some studies.

Key Studies & References

1. Less Pain with Intra-Articular Hyaluronic Acid Injections for Knee Osteoarthritis Compared to Placebo: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
2. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis
3. Study Details: MONOVISC for Hip Joint Pain Relief Due to Osteoarthritis (NCT04204083) - Open Label

Common questions about MONOVISC (FAQ)

Q: Is MONOVISC the same type of treatment as a steroid or cortisone shot?

Official documentation classifies MONOVISC as a viscosupplementation agent, which is a different treatment class than a steroid or cortisone injection. The function of viscosupplementation is to improve the mechanical properties of the joint fluid. Corticosteroids are listed in regulatory sources as an alternative therapy.

Q: Is MONOVISC considered a painkiller or analgesic?

MONOVISC is categorized as a viscosupplementation agent, not a simple analgesic or painkiller. The treatment is officially indicated for knee pain in patients whose symptoms have not responded adequately to simple painkillers. Its primary function is a biomechanical one, supplementing the joint fluid.

Q: Do most patients feel immediate pain relief after the injection?

Clinical study summaries indicate that the onset of noticeable pain relief usually begins at approximately two weeks after the injection. It is not intended to provide immediate relief in the same way simple painkillers might.

Q: How long does it usually take for the effects of MONOVISC to become noticeable?

The relief of osteoarthritis knee pain has been shown to start at approximately two weeks following the single injection. This is the timeline observed in clinical studies for when the effects become apparent.

Q: Can a delayed reaction occur days after receiving a MONOVISC injection?

Official information describes expected local side effects, such as pain and swelling at the injection site, as generally mild and transient. These reactions are not expected to last long. Patients can discuss any concerns, especially if pain or swelling persists or significantly worsens, with the healthcare professional who performed the injection.

Q: How does the action of MONOVISC differ from a lubricant for the joint?

MONOVISC is a viscosupplementation agent that works by restoring the essential viscosity (thickness) and elasticity (stretchiness) of the joint fluid. By physically restoring these properties, the treatment improves the joint's natural lubricating and shock-absorbing functions.

Q: What is the expected duration of the relief provided by MONOVISC?

Clinical study summaries indicate that the relief of osteoarthritis knee pain provided by MONOVISC may last for up to six months following the single injection.

Q: Are there any described long-term safety concerns associated with repeated use of MONOVISC?

The official prescribing information states that the safety and effectiveness of a repeat course of treatment (more than one course) have not been established by regulatory authorities. Additionally, long-term effects beyond the period of clinical study are not fully established.

Q: Is it safe to take over-the-counter pain relievers like ibuprofen or aspirin around the time of the injection?

Official prescribing information does not document any systemic metabolic interactions with other medicines. The regulatory profile for MONOVISC does not list or document any significant systemic interactions with other drugs.

Q: What classes of other medicines, if any, have described interactions with MONOVISC?

MONOVISC has two main administration constraints. Official instructions state that disinfectants containing quaternary ammonium salts should not be used for skin preparation before the injection, as this chemical causes the product to precipitate. Also, the safety of using it with other injectable substances inside the joint has not been established.

Q: Can MONOVISC be used if a patient has a known allergy to birds or eggs?

MONOVISC is derived from bacterial fermentation and is explicitly stated as non-avian sourced. The official contraindications are not related to egg or avian proteins. They focus on known hypersensitivity to the product itself, or to proteins from gram-positive bacteria.

Q: Is MONOVISC suitable for use by older adults or elderly patients?

Official prescribing information establishes the safety and effectiveness of MONOVISC in the adult population (patients over 21 years of age). There is no explicit upper age limit or specific restriction for older adults defined in the regulatory documents.

Q: Why do some people compare MONOVISC to other similar products like Synvisc or Orthovisc?

MONOVISC is one of several FDA-approved viscosupplementation agents. Official documents describe the MONOVISC dose as delivering a comparable amount of Sodium Hyaluronate to the multi-injection regimen of a similar product, ORTHOVISC, providing context for the comparisons users make.

Q: Is MONOVISC considered a permanent or curative treatment for osteoarthritis?

MONOVISC is described as a symptomatic treatment for the pain associated with knee osteoarthritis. Since it is comprised of a resorbable substance and the pain relief lasts for up to six months, official information indicates it is not a permanent or curative treatment.

Q: Is it typical for the knee to feel temporarily stiff after receiving the injection?

Joint stiffness is one of the potential post-injection adverse events documented in clinical studies associated with MONOVISC use. This is a potential, temporary reaction following the administration.

Q: How is the material in MONOVISC naturally broken down by the body?

MONOVISC is described in product information as a resorbable fluid. The classification as a resorbable fluid means the material is broken down and eliminated by the body's natural processes over time.

Q: What level of activity is generally expected or allowed right after the procedure?

The official constraint states that strenuous or prolonged weight-bearing activities should be avoided for approximately 48 hours following the injection. Examples of activities restricted by the official constraint include jogging, tennis, or heavy lifting.

Q: Is it possible for the effects of MONOVISC to wear off faster than expected?

Clinical studies provide an average observation that the effects may last for up to six months. However, official research documents state that findings describe group patterns, and do not determine whether an individual will respond similarly to the observations in the studies.

Official Storage and Disposal Guidelines

MONOVISC must be stored under specific conditions to maintain its integrity and sterility, as directed by official regulatory labeling.

Storage Category	Requirement
Temperature	Store at room temperature, specifically below 77 F (25 C).
Handling Precaution	Do not freeze.
Packaging	Keep in the original package. Do not use if the package has been opened or damaged.
In-Use Stability	The pre-filled syringe is for single use only. The contents must be used immediately after opening.
Preparation Note	Do not use disinfectants containing quaternary ammonium salts for skin preparation, as they may cause the product to precipitate.
Disposal	Any unused portion of MONOVISC must be discarded after administration.

These guidelines ensure the product remains sterile and effective until the moment of use, strictly adhering to the mandated storage and handling requirements for this single-use product.